Logo image
Rheumatoid arthritis oral abstractsO01. Efficacy and Safety of Baricitinib Versus Placebo and Adalimumab in Patients with Moderately to Severely Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Summary Results from the 52-Week Phase 3 RA-Beam Study
Article de revue scientifique   Avec comité de lecture

Rheumatoid arthritis oral abstractsO01. Efficacy and Safety of Baricitinib Versus Placebo and Adalimumab in Patients with Moderately to Severely Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Summary Results from the 52-Week Phase 3 RA-Beam Study

Peter C. Taylor, Marek Krogulec, Anna Dudek, Jean Dudler, Edit Drescher, Regina Cseuz, Rasa Kausiene, Daina Andersone, Dalia Unikiene, Juan Sanchez Burson, …
Rheumatology (Oxford, England), Vol.56(suppl_2)
01/04/2017

Indicateurs

1 Consultations de la notice

Détails

Logo image